Robust Brain Correlates of Cognitive Performance in Psychosis and its Prodrome
Ward H, Beermann A, Xie J, Yildiz G, Felix K, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Coleman M, Bouix S, Holt D, Öngür D, Breier A, Shenton M, Heckers S, Halko M, Lewandowski K, Brady R. Robust Brain Correlates of Cognitive Performance in Psychosis and its Prodrome. Biological Psychiatry 2024 PMID: 39032726, DOI: 10.1016/j.biopsych.2024.07.012.Peer-Reviewed Original ResearchAuditory continuous performance taskConnectome-wide association studiesEarly psychosisCognitive performanceNorth American Prodrome Longitudinal Study 2At-risk individualsCorrelates of cognitive performanceBrain-cognition relationshipsBrain-phenotype relationshipsBrain-behavior associationsContinuous performance taskEarly-course psychosisLongitudinal Study 2Resting-state fMRIProspective study of individualsHuman Connectome ProjectPsychosis onsetStudy of individualsPsychosisStudy 2Performance tasksNeurocognitive impairmentCognitive instrumentsHealthy participantsRobust associationsPlasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Byrne J, Healy C, Föcking M, Heurich M, Susai S, Mongan D, Wynne K, Kodosaki E, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, Jeffries C, Perkins D, Cotter D. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain Behavior And Immunity 2024, 119: 188-196. PMID: 38555993, DOI: 10.1016/j.bbi.2024.03.049.Peer-Reviewed Original ResearchNegative symptomsDepressive symptomsScale of Psychosis-risk SymptomsMeasures of negative symptomsNorth American Prodrome Longitudinal Study 2Psychosis-risk symptomsClinical high riskPrognostic factorsLongitudinal Study 2Positive symptomsNAPLS 2Psychotic disordersAntipsychotic usePsychotic experiencesCannabis useSuicidal ideationAntidepressant useStudy 2Regulation groupQuality of life of individualsGroup factorsCurrent treatment optionsDemographic prognostic factorsPsychosisCoagulation proteinsProteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study
Byrne J, Healy C, Föcking M, Susai S, Mongan D, Wynne K, Kodosaki E, Heurich M, de Haan L, Hickie I, Smesny S, Thompson A, Markulev C, Young A, Schäfer M, Riecher-Rössler A, Mossaheb N, Berger G, Schlögelhofer M, Nordentoft M, Chen E, Verma S, Nieman D, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, McGorry P, Amminger P, Cagney G, Nelson B, Jeffries C, Perkins D, Cotter D. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin 2024, 50: 579-588. PMID: 38243809, PMCID: PMC11059811, DOI: 10.1093/schbul/sbad184.Peer-Reviewed Original ResearchClinical high riskTransition to psychosisAssociated with transition to psychosisClinical high-risk cohortNorth American Prodrome Longitudinal Study 2Predicting transition to psychosisDevelopment of psychosisLongitudinal Study 2Group levelPlasma proteomics dataCHR participantsPsychosis riskPrediction of transitionPsychosisStudy 2High riskLongitudinal associationsStudy follow-up periodRandomized controlled trialsLogistic regression modelsMultiple comparisonsPrimary outcomeProteomic biomarkersControlled trialsGlycoprotein 1